Author:
Escudero Diogo O.,Shirodkar Samir P.,Lokeshwar Vinata B.
Reference96 articles.
1. Abdel-Fattah R, Challen C, Griffiths TR, Robinson MC, Neal DE, Lunec J (Jun 1998) Alterations of TP53 in microdissected transitional cell carcinoma of the human urinary bladder: high frequency of TP53 accumulation in the absence of detected mutations is associated with poor prognosis. Br J Cancer 77(12):2230–2238
2. Abdel-Rahman SZ, Anwar WA, Abdel-Aal WE, Ghoneim MA, Au WW (28 Oct 1997) The CYP2D6 extensive metabolizer genotype is associated with increased risk for bladder cancer. Cancer Lett 119(1):115–122
3. Altayli E, Gunes S, Yilmaz AF, Goktas S, Bek Y (2009) CYP1A2, CYP2D6, GSTM1, GSTP1, and GSTT1 gene polymorphisms in patients with bladder cancer in a Turkish population. Int Urol Nephrol 41(2):259–266
4. Armstrong AB, Wang M, Eble JN, MacLennan GT, Montironi R, Tan PH, Lopez-Beltran A, Zhang S, Baldridge LA, Spartz H, Cheng L (Jan 2009) TP53 mutational analysis supports monoclonal origin of biphasic sarcomatoid urothelial carcinoma (carcinosarcoma) of the urinary bladder. Mod Pathol 22(1):113–118
5. Bakkar AA, Wallerand H, Radvanyi F, Lahaye JB, Pissard S, Lecerf L et al (2003) FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder. Cancer Res 63:8108
Cited by
9 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献